{"gene":"IL20","run_date":"2026-04-28T18:06:54","timeline":{"discoveries":[{"year":2001,"finding":"IL-20 signals through two distinct receptor complexes: a type I complex (IL-20Rα/IL-20Rβ) and a type II complex (IL-22R1/IL-20Rβ); binding of IL-20 to either complex results in STAT3 phosphorylation and activation of STAT-binding promoter elements. IL-19 signals only through type I, while mda-7/IL-24 signals through both.","method":"Receptor binding assays, STAT3 phosphorylation assays, STAT-responsive reporter gene assays in cell lines","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 — direct biochemical receptor-ligand binding and signaling assays with multiple cytokines/receptor combinations; foundational paper replicated across the field","pmids":["11564763"],"is_preprint":false},{"year":2007,"finding":"IL-20 induces acanthosis, upregulates S100A7 and keratin 16, and causes persistent nuclear STAT3 activation in reconstituted human epidermis (RHE); it also induces a gene-expression profile consistent with inflammatory responses, wound healing, and altered keratinocyte differentiation.","method":"Reconstituted human epidermis (3D skin model) treated with recombinant cytokines; immunostaining for STAT3 nuclear localization; microarray gene expression analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 — reconstituted tissue model with multiple orthogonal readouts (histology, immunostaining, transcriptomics); replicated by multiple labs","pmids":["17277128"],"is_preprint":false},{"year":2009,"finding":"IL-20 causes psoriasis-like morphological changes (acanthosis, inhibited keratinocyte terminal differentiation, STAT3 upregulation) in 3D human epidermis models, acting directly on keratinocytes; these effects are distinct from those of IFN-γ and IL-17.","method":"3D human epidermis model treated with IL-20 vs. other cytokines; histological analysis; STAT3 assays; differentiation-gene expression","journal":"Journal of molecular medicine","confidence":"High","confidence_rationale":"Tier 1–2 — reconstituted 3D epidermal model with multiple cytokine comparisons and STAT3-dependence testing; independently corroborates PMID 17277128","pmids":["19330474"],"is_preprint":false},{"year":2009,"finding":"IL-22 induces IL-20 mRNA and protein production in human keratinocytes; IL-17A and TNF-α also induce IL-20 in keratinocytes, and some IL-22 effects on differentiation-regulating genes are partially mediated by endogenously secreted IL-20 (as shown by anti-IL-20 antibody blockade).","method":"Keratinocyte cell culture with recombinant cytokines; RT-PCR and ELISA for IL-20; neutralizing anti-IL-20 antibody blockade of IL-22 effects; correlation of IL-20 and IL-22 in patient skin","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (ELISA, PCR, antibody neutralization, in vivo mouse model); demonstrates epistatic relationship between IL-22 and IL-20 in keratinocytes","pmids":["19830738"],"is_preprint":false},{"year":2006,"finding":"IL-20 is produced by monocytes (especially myeloid-derived cells) and keratinocytes; IL-20 treatment of keratinocytes upregulates IFN-γ-induced and disease-related genes as determined by microarray; plastic adhesion, β2-integrin activation, and TNF-α stimulate monocyte IL-20 expression.","method":"Cell-type–specific IL-20 expression by RT-PCR; in vitro monocyte/keratinocyte stimulation assays; microarray of IL-20-treated keratinocytes; immunohistochemistry with cell-type markers in patient skin","journal":"Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2–3 — multiple in vitro assays and microarray; single lab, no functional rescue","pmids":["16645593"],"is_preprint":false},{"year":2009,"finding":"IL-20R2 (IL-20Rβ) signaling directly down-regulates antigen-specific CD4+ and CD8+ T cell responses: IL-20R2-knockout mice show elevated IFN-γ and IL-2 from T cells stimulated in vitro and enhanced antigen-specific IFN-γ+ T cell responses in vivo to DNA vaccines.","method":"IL-20R2 knockout mice; in vitro T-cell stimulation with Con A or anti-CD3/CD28; DNA vaccine model; contact hypersensitivity model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with defined cellular and in vivo phenotype; multiple functional readouts","pmids":["19124723"],"is_preprint":false},{"year":2007,"finding":"IL-20 activates multiple intracellular signaling pathways in endothelial cells (JAK2/STAT5, ERK1/2, Akt phosphorylation; Rac/Rho GTPase activation; intracellular calcium release) and promotes endothelial tube formation without affecting proliferation or motility; in vivo delivery to ischemic rat hindlimb significantly improves arteriogenesis and blood perfusion.","method":"Signaling assays (kinase phosphorylation) in large and microvascular endothelial cells; tube formation assay; rat hindlimb ischemia model with IL-20 delivery","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1–2 — mechanistic in vitro signaling with multiple pathway readouts plus in vivo functional model","pmids":["17878297"],"is_preprint":false},{"year":2011,"finding":"IL-20 mediates osteoclastogenesis by up-regulating RANK expression in osteoclast precursor cells and RANKL in osteoblasts; IL-20R1-deficient mice have higher bone mineral density; anti-IL-20 monoclonal antibody completely inhibits osteoclast differentiation induced by M-CSF+RANKL in vitro and protects against ovariectomy-induced bone loss in vivo.","method":"In vitro osteoclast differentiation assay with recombinant IL-20 and anti-IL-20 mAb; RT-PCR/Western blot for RANK/RANKL; IL-20R1 knockout mice with DEXA bone density measurement; OVX mouse model","journal":"Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro mechanism (RANK/RANKL upregulation) + genetic KO + in vivo pharmacological blockade with multiple readouts","pmids":["21844205"],"is_preprint":false},{"year":2013,"finding":"IL-19, IL-20, and IL-24 signaling through type I and type II IL-20 receptors promotes cutaneous S. aureus infection by downregulating IL-1β- and IL-17A-dependent antimicrobial pathways in keratinocytes and skin; antibody blockade of the IL-20 receptor improved infection outcomes in mice.","method":"Mouse S. aureus infection model; anti-IL-20R antibody blockade; IL-1β and IL-17A cytokine measurement; human keratinocyte S. aureus exposure assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — in vivo infection model with antibody blockade plus human cell data; defines epistatic pathway position of IL-20R signaling upstream of IL-1β/IL-17A","pmids":["23793061"],"is_preprint":false},{"year":2009,"finding":"IL-20 activates lymphatic endothelial cells via PI3K/Akt, ERK1/2, mTOR, and eNOS phosphorylation pathways, induces NO production, causes actin polymerization and tube formation in Matrigel, and drives cell migration at rates comparable to VEGF-C; these effects are PI3K- and mTOR-dependent.","method":"Calcium imaging; Akt, ERK1/2, mTOR, eNOS phosphorylation assays; NO production assay; Matrigel tube formation; sprouting/migration assay; pathway inhibitors (wortmannin, rapamycin, PD98059)","journal":"Microvascular research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple signaling readouts with pharmacological inhibitors; single lab","pmids":["19281830"],"is_preprint":false},{"year":2004,"finding":"In glioblastoma cells, LPS induces IL-20 expression through a MyD88- and p38 MAP kinase–dependent signaling mechanism (not requiring de novo protein synthesis); dexamethasone inhibits LPS-induced IL-20 expression, indicating glucocorticoid-mediated negative feedback.","method":"Primary glial cell and RAW264.7 cultures; LPS stimulation; MyD88-KO mouse-derived glial cells; protein synthesis inhibitor (puromycin/cycloheximide); p38 inhibitor SB203580; RT-PCR","journal":"Brain research. Molecular brain research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO (MyD88) plus pharmacological dissection; single lab","pmids":["15519673"],"is_preprint":false},{"year":2009,"finding":"IL-20 is regulated by hypoxia-inducible factor-1α (HIF-1α): two putative hypoxia response elements in the IL-20 promoter are functional (luciferase reporter assays), CoCl2-induced HIF-1α drives IL-20 expression in multiple cell types, and HIF-1α inhibition suppresses this; in an ischemic stroke rat model, IL-20 is upregulated in peri-infarcted glia-like cells and anti-IL-20 mAb reduces brain infarct size.","method":"CoCl2 hypoxia mimicry; HIF-1α inhibition; luciferase promoter activity assays; RT-PCR in multiple cell lines; rat MCAO ischemic stroke model; anti-IL-20 mAb treatment; JAK2/STAT3 and ERK1/2 signaling assays in glioblastoma cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 — promoter mutagenesis/reporter + genetic inhibition + in vivo model with functional readout","pmids":["19342680"],"is_preprint":false},{"year":2014,"finding":"IL-20 activates quiescent hepatic stellate cells, upregulates TGF-β1 in both hepatocytes and stellate cells, and promotes stellate cell proliferation/migration and collagen I production; in vivo, IL-20R1-deficient mice are protected from CCl4-induced liver fibrosis, and anti-IL-20 antibodies attenuate fibrosis by reducing TGF-β1, TNF-α, and extracellular matrix accumulation.","method":"In vitro hepatic stellate cell and hepatocyte stimulation; RT-PCR/ELISA for TGF-β1, collagen; CCl4 mouse liver fibrosis model; IL-20R1 KO mice; anti-IL-20 and anti-IL-20R1 mAb treatment","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO + pharmacological blockade + in vitro mechanism; multiple endpoints","pmids":["24763901"],"is_preprint":false},{"year":2015,"finding":"IL-20 mRNA is post-transcriptionally regulated in psoriatic keratinocytes by the RNA-binding protein HuR, which relocates to the cytoplasm and stabilizes IL-20 transcripts; AMPK activity is severely impaired in psoriatic epidermis and drives HuR cytoplasmic relocalization; in vivo AMPK inhibition in mouse epidermis reproduces IL-20 overproduction, acanthosis, and hyperkeratosis.","method":"RNP-immunoprecipitation with high-throughput sequencing (RIP-Seq) from psoriatic skin; subcellular fractionation and HuR localization; AMPK activity assays; pharmacological AMPK inhibition in mouse epidermis; IL-20 mRNA stability assays","journal":"Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 1–2 — RIP-Seq + in vitro mRNA stability + in vivo AMPK inhibition with defined phenotypic readout","pmids":["26176762"],"is_preprint":false},{"year":2016,"finding":"Estrogen (E2) induces IL-20 expression in breast cancer cells through ER-α recruiting the histone methyltransferase KMT2B to the IL-20 promoter, leading to H3K4 methylation; depletion of KMT2B or IL-20 reduces cell proliferation, colony formation, and causes cell cycle arrest.","method":"ChIP assay for KMT2B and H3K4 methylation at IL-20 promoter; siRNA knockdown of KMT2B; cell proliferation and colony formation assays; qRT-PCR","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus functional KD; single lab","pmids":["27806114"],"is_preprint":false},{"year":2017,"finding":"A transcriptional complex of ERα, GATA3, FOXA1, and ELL3 regulates IL-20 expression in ER+ breast cancer cells; ERα and GATA3 activate IL-20 transcription while FOXA1 represses it; ELL3 associates with ERα to increase its binding affinity to the IL-20 promoter and may prevent FOXA1 binding.","method":"ChIP assay; co-immunoprecipitation of the transcriptional complex; siRNA knockdown of individual factors; luciferase reporter assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP + ChIP + reporter assays; single lab","pmids":["28514748"],"is_preprint":false},{"year":2019,"finding":"IL-20 receptor signaling (particularly via IL-19) in the imiquimod psoriasis model suppresses dermal CCL2 chemokine production and thereby reduces recruitment of CCL2-driven inflammatory cells including IL-17A-producing γδ T cells, constituting a negative feedback loop since IL-17A induces IL-19 in keratinocytes.","method":"Imiquimod-induced psoriasis mouse model; IL-20R knockout/deficient mice; cytokine and chemokine measurements; flow cytometry of infiltrating immune cells","journal":"Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo genetic model with defined cellular mechanism; single lab","pmids":["31252033"],"is_preprint":false},{"year":2017,"finding":"IL-20 inhibits key inflammatory functions of activated human neutrophils (phagocytosis, granule exocytosis, migration) by modifying actin polymerization; neutrophils upregulate IL-20R chain expression upon migration and activation under S. aureus infection conditions.","method":"Primary human neutrophil isolation; in vitro migration and activation assays; actin polymerization assay; phagocytosis assay; granule exocytosis assay; IL-20R expression by flow cytometry","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional neutrophil assays with mechanistic link to actin; single lab","pmids":["28424238"],"is_preprint":false},{"year":2020,"finding":"IL-20 promotes cardiomyocyte apoptosis under hypoxia/reoxygenation by activating the PKC/NADPH oxidase pathway, increasing intracellular Ca2+, elevating oxidative stress, and downregulating AKT; these effects are observed in H9C2 cardiomyoblasts, primary cardiomyocytes, and in rat hearts undergoing I/R injury.","method":"H9C2 and primary cardiomyocyte cell culture; hypoxia/reoxygenation model; PKC inhibition; NADPH oxidase activity; Ca2+ imaging; AKT phosphorylation assay; rat I/R model","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 — pathway dissection with inhibitors plus in vivo model; single lab","pmids":["31953216"],"is_preprint":false},{"year":2021,"finding":"IL-20 promotes adipocyte differentiation and polarizes bone marrow-derived macrophages toward M1 type; it induces inflammation and macrophage retention in adipose tissue by upregulating TNF-α, MCP-1, netrin 1, and unc5b in macrophages and induces insulin resistance by inhibiting glucose uptake via the SOCS-3 pathway in mature adipocytes.","method":"In vitro adipocyte differentiation assay; BMDM polarization assay; ELISA/Western blot for signaling; glucose uptake assay; SOCS-3 pathway analysis; HFD mouse model with anti-IL-20 mAb treatment","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple in vitro assays with defined pathway (SOCS-3) plus in vivo model; single lab","pmids":["34403503"],"is_preprint":false},{"year":2024,"finding":"IL-20 controls resolution of experimental colitis by signaling in intestinal epithelial cells (IECs) to suppress IFN/STAT2-driven necroptotic cell death; IL-20 activates STAT3 and suppresses IFN-STAT2 signaling in IECs; Il20- and Il20rb-deficient mice are more susceptible to DSS colitis; IL-20 blockade of STAT2 necroptosis in IEC-derived organoids was demonstrated by co-immunoprecipitation and confocal microscopy.","method":"Il20 and Il20rb knockout mice; DSS colitis model; IEC-derived 3D organoids; RNA-Seq; co-immunoprecipitation; STAT2 IEC-specific knockout mice; Western blot for STAT3/STAT2; RNAScope","journal":"Gut","confidence":"High","confidence_rationale":"Tier 1–2 — multiple genetic KO models + organoids + co-IP + in vivo disease model with mechanistic pathway (STAT2 necroptosis) identified","pmids":["37884352"],"is_preprint":false},{"year":2022,"finding":"IL-20 subfamily cytokines (including IL-20) impair the oesophageal epithelial barrier in eosinophilic oesophagitis by downregulating filaggrin and cornified envelope genes via the MAPK/ERK1/2 pathway; Il20R2-deficient mice show preserved filaggrin expression and attenuated EoE; ERK1/2 blockade prevents barrier impairment in patient-derived ALI cultures.","method":"Patient-derived oesophageal organoids and ALI cultures; RNA-Seq and mass spectrometry; Il20R2-/- EoE mouse model; ERK1/2 inhibition; immunostaining for filaggrin","journal":"Gut","confidence":"High","confidence_rationale":"Tier 1–2 — genetic KO + organoid models + proteomics + pathway inhibition with mechanistic readout","pmids":["35613844"],"is_preprint":false},{"year":2003,"finding":"IL-20 selectively enhances colony formation by CD34+ multipotential hematopoietic progenitors in vitro and in vivo (transgenic overexpression and direct administration in mice), with no effect on erythroid, granulocyte-macrophage, or megakaryocyte progenitors.","method":"In vitro colony formation assay of CD34+ progenitors; IL-20 transgenic mice; recombinant IL-20 administration to normal mice; progenitor enumeration and cell-cycle analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro + transgenic + direct in vivo administration; single lab with multiple modalities","pmids":["12855566"],"is_preprint":false},{"year":2005,"finding":"IL-20 downregulates COX-2 and PGE2 in human bronchial epithelial and endothelial cells through the IL-22R1/IL-20R2 receptor complex (as determined by flow cytometry of receptor expression and receptor blockade), and inhibits experimental angiogenesis via this COX-2 regulatory pathway.","method":"Flow cytometry for receptor expression; COX-2/PGE2 assays with receptor-blocking antibodies; in vitro angiogenesis assay with COX-2 pathway inhibition","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2–3 — receptor specificity established by blocking antibody + functional angiogenesis readout; single lab","pmids":["15950941"],"is_preprint":false}],"current_model":"IL-20 is a pleiotropic IL-10 family cytokine that signals through two heterodimeric receptor complexes (type I: IL-20Rα/IL-20Rβ; type II: IL-22R1/IL-20Rβ), activating JAK-STAT3 and multiple downstream pathways (ERK1/2, Akt, PKC/NADPH oxidase, MAPK) to regulate keratinocyte proliferation and barrier function, inhibit terminal differentiation via HIF-1α- and HuR/AMPK-controlled expression, promote osteoclastogenesis via RANK/RANKL upregulation, facilitate arteriogenesis and lymphangiogenesis through endothelial tube formation, drive hepatic stellate cell activation and fibrosis via TGF-β1, protect intestinal epithelial cells from IFN/STAT2-driven necroptosis, and modulate T cell and neutrophil responses through IL-20Rβ signaling, while its own transcription is induced downstream of IL-22 and TNF-α in keratinocytes and regulated epigenetically by KMT2B/ERα and post-transcriptionally by AMPK/HuR."},"narrative":{"teleology":[{"year":2001,"claim":"Identifying IL-20's dual receptor usage and primary signaling output resolved how a single cytokine activates STAT3 through two distinct heterodimeric receptor complexes, establishing the signaling framework for all subsequent functional studies.","evidence":"Receptor binding assays and STAT3 phosphorylation/reporter assays in transfected cell lines","pmids":["11564763"],"confidence":"High","gaps":["Crystal structure of IL-20–receptor complexes not determined","Relative contribution of each receptor complex in different tissues unknown","Downstream transcriptional targets of STAT3 activation not mapped"]},{"year":2003,"claim":"Demonstrating that IL-20 selectively expands multipotential hematopoietic progenitors revealed an unexpected role beyond epithelial biology, though the receptor complex mediating this effect was not identified.","evidence":"Colony formation assays of CD34+ progenitors in vitro; IL-20 transgenic mice and recombinant protein administration in vivo","pmids":["12855566"],"confidence":"Medium","gaps":["Receptor complex responsible on hematopoietic progenitors not determined","Not independently replicated","Physiological significance of progenitor expansion unclear"]},{"year":2004,"claim":"Elucidating the transcriptional induction of IL-20 by LPS through MyD88 and p38 MAPK established that IL-20 is a direct innate immune response gene that does not require de novo protein synthesis for its induction.","evidence":"LPS stimulation of glial cells from wild-type and MyD88-knockout mice; p38 inhibitor; protein synthesis inhibitors; RT-PCR","pmids":["15519673"],"confidence":"Medium","gaps":["Findings in glioblastoma cells; relevance to myeloid cells not directly shown","Promoter elements mediating LPS response not mapped"]},{"year":2005,"claim":"Showing that IL-20 suppresses COX-2/PGE2 specifically through the type II receptor (IL-22R1/IL-20Rβ) in bronchial epithelial and endothelial cells provided the first evidence for receptor-complex-specific functional outcomes.","evidence":"COX-2/PGE2 assays with receptor-blocking antibodies; angiogenesis assay","pmids":["15950941"],"confidence":"Medium","gaps":["Anti-angiogenic effect via COX-2 contrasts with pro-arteriogenic findings in other endothelial contexts; cell-type specificity unresolved","Single lab finding"]},{"year":2007,"claim":"Two independent studies using 3D reconstituted human epidermis and endothelial signaling assays established that IL-20 drives keratinocyte acanthosis with persistent nuclear STAT3 and promotes arteriogenesis via JAK2/STAT5, ERK1/2, and Akt in endothelial cells, revealing tissue-specific pathway utilization.","evidence":"3D skin models with immunostaining and microarray; endothelial signaling assays and rat hindlimb ischemia model","pmids":["17277128","17878297"],"confidence":"High","gaps":["Whether arteriogenesis requires STAT3 or alternative STATs not resolved","In vivo confirmation of acanthosis mechanism in human psoriasis lacking"]},{"year":2009,"claim":"A convergence of studies established that IL-20 operates as a downstream effector of IL-22 in keratinocytes, is transcriptionally regulated by HIF-1α under hypoxia, activates lymphangiogenic signaling via PI3K/Akt/mTOR/eNOS, inhibits keratinocyte terminal differentiation, and dampens T cell responses via IL-20Rβ, greatly expanding the cytokine's functional portfolio.","evidence":"IL-22 → IL-20 induction in keratinocytes with neutralizing antibody; HIF-1α promoter reporter and rat stroke model; lymphatic endothelial cell signaling assays; 3D epidermis differentiation; IL-20R2 knockout T cell assays and DNA vaccine model","pmids":["19830738","19342680","19281830","19330474","19124723"],"confidence":"High","gaps":["Direct binding of HIF-1α to IL-20 promoter HREs shown by reporter but not ChIP","Whether T cell suppression is mediated by IL-20 vs. other IL-20Rβ ligands not resolved","In vivo lymphangiogenesis not demonstrated"]},{"year":2011,"claim":"Demonstrating that IL-20 drives osteoclastogenesis through RANK/RANKL upregulation—with IL-20R1 KO mice showing higher bone density and anti-IL-20 mAb preventing ovariectomy-induced bone loss—established IL-20 as a bone-remodeling cytokine.","evidence":"In vitro osteoclast differentiation with anti-IL-20 mAb; IL-20R1 KO mice; ovariectomy model","pmids":["21844205"],"confidence":"High","gaps":["Relative contribution of IL-20 vs. IL-19/IL-24 to osteoclastogenesis in vivo not dissected","Signaling pathway downstream of RANK induction not traced"]},{"year":2013,"claim":"Showing that IL-20 receptor signaling suppresses IL-1β- and IL-17A-dependent antimicrobial pathways during S. aureus skin infection, and that receptor blockade improves outcomes, reframed IL-20 subfamily signaling as a host susceptibility factor exploitable by pathogens.","evidence":"Mouse S. aureus skin infection; anti-IL-20R antibody; cytokine/chemokine measurements; keratinocyte assays","pmids":["23793061"],"confidence":"High","gaps":["Specific contribution of IL-20 vs. IL-19/IL-24 in the infection model not separated","Mechanism of antimicrobial gene suppression at the promoter level unknown"]},{"year":2014,"claim":"Identifying IL-20 as an activator of hepatic stellate cells via TGF-β1 induction, with IL-20R1 KO mice protected from CCl4-induced fibrosis, extended IL-20's pathological roles to liver fibrogenesis.","evidence":"In vitro stellate cell/hepatocyte stimulation; CCl4 fibrosis model in IL-20R1 KO mice and with anti-IL-20 mAb","pmids":["24763901"],"confidence":"High","gaps":["Signaling pathway from IL-20R to TGF-β1 transcription not delineated","Whether IL-20 acts on cholangiocytes or other hepatic cell types not examined"]},{"year":2015,"claim":"Discovering that AMPK impairment in psoriatic epidermis causes cytoplasmic HuR relocalization and IL-20 mRNA stabilization provided a post-transcriptional mechanism for IL-20 overproduction in disease and identified AMPK as an upstream regulator.","evidence":"RIP-Seq from psoriatic skin; HuR subcellular fractionation; AMPK activity assays; in vivo AMPK inhibition in mouse epidermis","pmids":["26176762"],"confidence":"High","gaps":["Specific HuR binding site on IL-20 mRNA not mapped","Whether AMPK restoration is sufficient to normalize IL-20 in human psoriasis not tested"]},{"year":2016,"claim":"Revealing that estrogen/ERα recruits KMT2B to the IL-20 promoter for H3K4 methylation-dependent activation in breast cancer cells uncovered an epigenetic regulatory axis linking hormone signaling to IL-20 expression.","evidence":"ChIP for KMT2B and H3K4me at IL-20 promoter; siRNA knockdown; proliferation and colony assays in breast cancer cells","pmids":["27806114"],"confidence":"Medium","gaps":["Contribution of IL-20 to breast tumor growth in vivo not tested","Whether KMT2B is required for IL-20 expression in non-cancer contexts unknown"]},{"year":2017,"claim":"Parallel studies showed that IL-20 inhibits neutrophil effector functions (phagocytosis, migration) by disrupting actin dynamics and that its receptor-mediated signaling suppresses CCL2-dependent inflammatory cell recruitment in psoriasis, consolidating IL-20 as an immunosuppressive feedback cytokine.","evidence":"Primary human neutrophil functional assays with actin polymerization readouts; imiquimod psoriasis model in IL-20R KO mice with flow cytometry","pmids":["28424238","31252033"],"confidence":"Medium","gaps":["Direct molecular target of IL-20 on actin regulatory machinery not identified","Psoriasis feedback loop data primarily reflect IL-19 rather than IL-20 specifically"]},{"year":2020,"claim":"Demonstrating that IL-20 promotes cardiomyocyte apoptosis via PKC/NADPH oxidase-mediated oxidative stress and Ca²⁺ overload during ischemia-reperfusion extended IL-20's injury-promoting role to the heart.","evidence":"Hypoxia/reoxygenation in H9C2 cells and primary cardiomyocytes; PKC inhibition; rat I/R model","pmids":["31953216"],"confidence":"Medium","gaps":["Receptor complex mediating cardiac effects not identified","Single lab; not independently replicated","Whether anti-IL-20 is cardioprotective in clinically relevant models unknown"]},{"year":2021,"claim":"Showing that IL-20 promotes adipogenesis, M1 macrophage polarization, and insulin resistance through SOCS-3-mediated glucose uptake inhibition identified IL-20 as a metabolic inflammation mediator in adipose tissue.","evidence":"Adipocyte differentiation and glucose uptake assays; BMDM polarization; anti-IL-20 mAb in HFD mice","pmids":["34403503"],"confidence":"Medium","gaps":["Receptor complex involved in adipocyte signaling not defined","Single lab; independent replication needed","Relative contribution vs. other IL-10 family members in metabolic syndrome unknown"]},{"year":2022,"claim":"Demonstrating that IL-20 subfamily cytokines impair esophageal barrier integrity by downregulating filaggrin via MAPK/ERK1/2, with Il20R2 KO mice protected from eosinophilic esophagitis, extended the barrier-disrupting paradigm beyond skin to mucosal epithelia.","evidence":"Patient-derived esophageal organoids and ALI cultures; RNA-Seq; Il20R2 KO EoE mouse model; ERK1/2 inhibition","pmids":["35613844"],"confidence":"High","gaps":["Individual contribution of IL-20 vs. IL-19/IL-24 not dissected","Whether filaggrin downregulation is transcriptional or post-transcriptional not resolved"]},{"year":2024,"claim":"Identifying IL-20 as a protector of intestinal epithelial cells from IFN/STAT2-driven necroptosis during colitis, through STAT3 activation that antagonizes STAT2 signaling, revealed a tissue-repair function and a mechanistic STAT3-vs-STAT2 axis governing epithelial cell fate.","evidence":"Il20 and Il20rb KO mice in DSS colitis; IEC-derived organoids; RNA-Seq; STAT2 IEC-specific KO; co-IP for STAT2 necroptotic complex","pmids":["37884352"],"confidence":"High","gaps":["Whether STAT3 directly inhibits STAT2 transcription or competes for shared cofactors unknown","Relevance to human IBD not yet confirmed with patient tissue functional studies"]},{"year":null,"claim":"Major open questions include the structural basis of IL-20's dual receptor engagement, the determinants of tissue-specific pathway activation (STAT3 vs. ERK vs. PKC), the individual contributions of IL-20 vs. other IL-20Rβ-utilizing cytokines in vivo, and whether IL-20 neutralization has therapeutic efficacy in human disease.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal structure of IL-20 bound to either receptor complex","No systematic comparison of IL-20 vs. IL-19 vs. IL-24 signaling outcomes in identical cell types","Clinical trial data for anti-IL-20 therapy absent from this literature"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,6,7,9,12,20]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,8,17]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,3,4,7,12]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,6,9,11,18,20]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,8,16,17]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[1,2,3,21]}],"complexes":[],"partners":["IL20RA","IL20RB","IL22RA1","STAT3","ELAVL1","KMT2B","ESR1"],"other_free_text":[]},"mechanistic_narrative":"IL-20 is a pleiotropic IL-10 family cytokine that orchestrates epithelial proliferation, barrier integrity, immune modulation, and tissue remodeling across multiple organ systems. It signals through two heterodimeric receptor complexes—IL-20Rα/IL-20Rβ (type I) and IL-22R1/IL-20Rβ (type II)—to activate STAT3, ERK1/2, PI3K/Akt, and PKC/NADPH oxidase pathways, driving keratinocyte hyperproliferation and inhibition of terminal differentiation (psoriasis-like acanthosis), promoting osteoclastogenesis via RANK/RANKL upregulation, activating hepatic stellate cells through TGF-β1 induction, facilitating arteriogenesis and lymphangiogenesis in endothelial cells, and protecting intestinal epithelial cells from IFN/STAT2-driven necroptosis [PMID:11564763, PMID:17277128, PMID:21844205, PMID:24763901, PMID:17878297, PMID:37884352]. IL-20 also suppresses adaptive and innate immune effector functions, dampening T cell cytokine production and neutrophil phagocytosis/migration, and impairs epithelial barrier function in the esophagus through MAPK/ERK1/2-dependent filaggrin downregulation [PMID:19124723, PMID:28424238, PMID:35613844]. Its own expression is induced downstream of IL-22, TNF-α, and LPS (via MyD88/p38), transcriptionally regulated by HIF-1α and an ERα/KMT2B/GATA3 complex, and post-transcriptionally stabilized by the RNA-binding protein HuR under conditions of impaired AMPK activity [PMID:19830738, PMID:19342680, PMID:26176762, PMID:27806114]."},"prefetch_data":{"uniprot":{"accession":"Q9NYY1","full_name":"Interleukin-20","aliases":["Cytokine Zcyto10"],"length_aa":176,"mass_kda":20.1,"function":"Pro-inflammatory and angiogenic cytokine mainly secreted by monocytes and skin keratinocytes that plays crucial roles in immune responses, regulation of inflammatory responses, hemopoiesis, as well as epidermal cell and keratinocyte differentiation (PubMed:17277128, PubMed:34403503). Enhances tissue remodeling and wound-healing activities and restores the homeostasis of epithelial layers during infection and inflammatory responses to maintain tissue integrity (PubMed:17277128). Affects multiple actin-mediated functions in activated neutrophils leading to inhibition of phagocytosis, granule exocytosis, and migration (PubMed:28424238). Exert its effects via the type I IL-20 receptor complex consisting of IL20RA and IL20RB (PubMed:11706020). Alternatively, can mediate its activity through a second receptor complex called type II IL-20 receptor complex composed of IL22RA1 and IL20RB (PubMed:11564763). Acts as an arteriogenic and vascular remodeling factory by activating a range of signaling processes including phosphorylations of JAK2 and STAT5 as well as activation of the serine and threonine kinases AKT and ERK1/2 (By similarity). Alternatively, can activate STAT3 phosphorylation and transcriptional activity in a JAK2, ERK1/2 and p38 MAPK-dependent manner in keratinocytes (PubMed:23614738)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q9NYY1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IL20","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IL20","total_profiled":1310},"omim":[{"mim_id":"607900","title":"FERM DOMAIN-CONTAINING KINDLIN 1; FERMT1","url":"https://www.omim.org/entry/607900"},{"mim_id":"605687","title":"INTERLEUKIN 19; IL19","url":"https://www.omim.org/entry/605687"},{"mim_id":"605621","title":"INTERLEUKIN 20 RECEPTOR, BETA; IL20RB","url":"https://www.omim.org/entry/605621"},{"mim_id":"605620","title":"INTERLEUKIN 20 RECEPTOR, ALPHA; IL20RA","url":"https://www.omim.org/entry/605620"},{"mim_id":"605619","title":"INTERLEUKIN 20; IL20","url":"https://www.omim.org/entry/605619"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Endoplasmic reticulum","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"adipose tissue","ntpm":1.6},{"tissue":"skin 1","ntpm":1.2}],"url":"https://www.proteinatlas.org/search/IL20"},"hgnc":{"alias_symbol":["ZCYTO10","IL10D","IL-20"],"prev_symbol":[]},"alphafold":{"accession":"Q9NYY1","domains":[{"cath_id":"1.20.1250.10","chopping":"25-176","consensus_level":"medium","plddt":97.465,"start":25,"end":176}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NYY1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NYY1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NYY1-F1-predicted_aligned_error_v6.png","plddt_mean":92.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IL20","jax_strain_url":"https://www.jax.org/strain/search?query=IL20"},"sequence":{"accession":"Q9NYY1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NYY1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NYY1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NYY1"}},"corpus_meta":[{"pmid":"17277128","id":"PMC_17277128","title":"The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17277128","citation_count":422,"is_preprint":false},{"pmid":"19330474","id":"PMC_19330474","title":"IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not.","date":"2009","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/19330474","citation_count":352,"is_preprint":false},{"pmid":"11564763","id":"PMC_11564763","title":"Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11564763","citation_count":339,"is_preprint":false},{"pmid":"25421700","id":"PMC_25421700","title":"The IL-20 subfamily of cytokines--from host defence to tissue homeostasis.","date":"2014","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25421700","citation_count":311,"is_preprint":false},{"pmid":"18405958","id":"PMC_18405958","title":"The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29.","date":"2008","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18405958","citation_count":256,"is_preprint":false},{"pmid":"17083366","id":"PMC_17083366","title":"Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs.","date":"2006","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17083366","citation_count":204,"is_preprint":false},{"pmid":"14764663","id":"PMC_14764663","title":"Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14764663","citation_count":145,"is_preprint":false},{"pmid":"19830738","id":"PMC_19830738","title":"The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis.","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19830738","citation_count":144,"is_preprint":false},{"pmid":"18281438","id":"PMC_18281438","title":"Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes.","date":"2008","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/18281438","citation_count":131,"is_preprint":false},{"pmid":"16365913","id":"PMC_16365913","title":"Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16365913","citation_count":123,"is_preprint":false},{"pmid":"23793061","id":"PMC_23793061","title":"Signaling via the IL-20 receptor inhibits cutaneous production of IL-1β and IL-17A to promote infection with methicillin-resistant Staphylococcus aureus.","date":"2013","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23793061","citation_count":106,"is_preprint":false},{"pmid":"17465720","id":"PMC_17465720","title":"IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases.","date":"2007","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/17465720","citation_count":98,"is_preprint":false},{"pmid":"15564140","id":"PMC_15564140","title":"Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism.","date":"2004","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15564140","citation_count":93,"is_preprint":false},{"pmid":"18061474","id":"PMC_18061474","title":"The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy.","date":"2007","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/18061474","citation_count":92,"is_preprint":false},{"pmid":"16043414","id":"PMC_16043414","title":"Detection of IL-20 and its receptors on psoriatic skin.","date":"2005","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/16043414","citation_count":91,"is_preprint":false},{"pmid":"19731362","id":"PMC_19731362","title":"IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression.","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19731362","citation_count":85,"is_preprint":false},{"pmid":"16645593","id":"PMC_16645593","title":"Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects.","date":"2006","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/16645593","citation_count":84,"is_preprint":false},{"pmid":"16778121","id":"PMC_16778121","title":"IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice.","date":"2006","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16778121","citation_count":78,"is_preprint":false},{"pmid":"20061404","id":"PMC_20061404","title":"IL-24 transgenic mice: in vivo evidence of overlapping functions for IL-20, IL-22, and IL-24 in the epidermis.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20061404","citation_count":76,"is_preprint":false},{"pmid":"28125663","id":"PMC_28125663","title":"IL-22R Ligands IL-20, IL-22, and IL-24 Promote Wound Healing in Diabetic db/db Mice.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28125663","citation_count":73,"is_preprint":false},{"pmid":"12941475","id":"PMC_12941475","title":"IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26.","date":"2003","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/12941475","citation_count":72,"is_preprint":false},{"pmid":"21844205","id":"PMC_21844205","title":"Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21844205","citation_count":71,"is_preprint":false},{"pmid":"16703417","id":"PMC_16703417","title":"IL-20: biological functions and clinical implications.","date":"2006","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/16703417","citation_count":69,"is_preprint":false},{"pmid":"22238453","id":"PMC_22238453","title":"Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22238453","citation_count":65,"is_preprint":false},{"pmid":"24763901","id":"PMC_24763901","title":"IL-20 and IL-20R1 antibodies protect against liver fibrosis.","date":"2014","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/24763901","citation_count":65,"is_preprint":false},{"pmid":"19342680","id":"PMC_19342680","title":"IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19342680","citation_count":63,"is_preprint":false},{"pmid":"30260500","id":"PMC_30260500","title":"IL-20 receptor cytokines in autoimmune diseases.","date":"2018","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/30260500","citation_count":62,"is_preprint":false},{"pmid":"15851011","id":"PMC_15851011","title":"mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer.","date":"2005","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15851011","citation_count":60,"is_preprint":false},{"pmid":"32929072","id":"PMC_32929072","title":"IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32929072","citation_count":59,"is_preprint":false},{"pmid":"30319661","id":"PMC_30319661","title":"The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30319661","citation_count":57,"is_preprint":false},{"pmid":"17878297","id":"PMC_17878297","title":"IL-20 is an arteriogenic cytokine that remodels collateral networks and improves functions of ischemic hind limbs.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17878297","citation_count":55,"is_preprint":false},{"pmid":"16710719","id":"PMC_16710719","title":"Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10.","date":"2006","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/16710719","citation_count":55,"is_preprint":false},{"pmid":"20864382","id":"PMC_20864382","title":"IL-20: biological functions mediated through two types of receptor complexes.","date":"2010","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20864382","citation_count":54,"is_preprint":false},{"pmid":"15889129","id":"PMC_15889129","title":"Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis.","date":"2005","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15889129","citation_count":53,"is_preprint":false},{"pmid":"19124723","id":"PMC_19124723","title":"IL-20 receptor 2 signaling down-regulates antigen-specific T cell responses.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19124723","citation_count":52,"is_preprint":false},{"pmid":"21251229","id":"PMC_21251229","title":"Research in practice: IL-22 and IL-20: significance for epithelial homeostasis and psoriasis pathogenesis.","date":"2011","source":"Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG","url":"https://pubmed.ncbi.nlm.nih.gov/21251229","citation_count":52,"is_preprint":false},{"pmid":"17263806","id":"PMC_17263806","title":"Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis.","date":"2007","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17263806","citation_count":51,"is_preprint":false},{"pmid":"22962576","id":"PMC_22962576","title":"Identification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22962576","citation_count":51,"is_preprint":false},{"pmid":"21073280","id":"PMC_21073280","title":"IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases.","date":"2010","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/21073280","citation_count":50,"is_preprint":false},{"pmid":"23207823","id":"PMC_23207823","title":"IL-10-- and IL-20--expressing epithelial and inflammatory cells are increased in patients with ulcerative colitis.","date":"2012","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23207823","citation_count":50,"is_preprint":false},{"pmid":"18758357","id":"PMC_18758357","title":"IL-20 may contribute to the pathogenesis of human intervertebral disc herniation.","date":"2008","source":"Spine","url":"https://pubmed.ncbi.nlm.nih.gov/18758357","citation_count":42,"is_preprint":false},{"pmid":"29681905","id":"PMC_29681905","title":"IL-19 and Other IL-20 Family Member Cytokines in Vascular Inflammatory Diseases.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29681905","citation_count":41,"is_preprint":false},{"pmid":"18479293","id":"PMC_18479293","title":"Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome.","date":"2008","source":"International journal of immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/18479293","citation_count":41,"is_preprint":false},{"pmid":"31311100","id":"PMC_31311100","title":"Interleukin (IL)-22 from IL-20 Subfamily of Cytokines Induces Colonic Epithelial Cell Proliferation Predominantly through ERK1/2 Pathway.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31311100","citation_count":40,"is_preprint":false},{"pmid":"19755128","id":"PMC_19755128","title":"Cloning of a novel interleukin (IL)-20-like gene in rainbow trout Oncorhynchus mykiss gives an insight into the evolution of the IL-10 family.","date":"2009","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19755128","citation_count":40,"is_preprint":false},{"pmid":"12855566","id":"PMC_12855566","title":"Selective enhancement of multipotential hematopoietic progenitors in vitro and in vivo by IL-20.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12855566","citation_count":38,"is_preprint":false},{"pmid":"15950941","id":"PMC_15950941","title":"IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15950941","citation_count":35,"is_preprint":false},{"pmid":"35613844","id":"PMC_35613844","title":"IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis.","date":"2022","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/35613844","citation_count":35,"is_preprint":false},{"pmid":"27818315","id":"PMC_27818315","title":"IL-20 promotes epithelial healing of the injured mouse cornea.","date":"2016","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/27818315","citation_count":35,"is_preprint":false},{"pmid":"21565488","id":"PMC_21565488","title":"IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF.","date":"2011","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/21565488","citation_count":35,"is_preprint":false},{"pmid":"16831294","id":"PMC_16831294","title":"Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-alpha.","date":"2006","source":"International journal of immunopathology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16831294","citation_count":34,"is_preprint":false},{"pmid":"23002091","id":"PMC_23002091","title":"Anti-IL-20 monoclonal antibody alleviates inflammation in oral cancer and suppresses tumor growth.","date":"2012","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/23002091","citation_count":32,"is_preprint":false},{"pmid":"19281830","id":"PMC_19281830","title":"IL-20 activates human lymphatic endothelial cells causing cell signalling and tube formation.","date":"2009","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/19281830","citation_count":31,"is_preprint":false},{"pmid":"22930279","id":"PMC_22930279","title":"IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab.","date":"2013","source":"Acta dermato-venereologica","url":"https://pubmed.ncbi.nlm.nih.gov/22930279","citation_count":30,"is_preprint":false},{"pmid":"22458549","id":"PMC_22458549","title":"Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.","date":"2012","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22458549","citation_count":30,"is_preprint":false},{"pmid":"32028746","id":"PMC_32028746","title":"IL-20 in Acute Kidney Injury: Role in Pathogenesis and Potential as a Therapeutic Target.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32028746","citation_count":28,"is_preprint":false},{"pmid":"27867753","id":"PMC_27867753","title":"Diabetic Wounds Exhibit Decreased Ym1 and Arginase Expression with Increased Expression of IL-17 and IL-20.","date":"2016","source":"Advances in wound care","url":"https://pubmed.ncbi.nlm.nih.gov/27867753","citation_count":27,"is_preprint":false},{"pmid":"28369789","id":"PMC_28369789","title":"Increased interleukin (IL)-20 and IL-24 target osteoblasts and synovial monocytes in spondyloarthritis.","date":"2017","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28369789","citation_count":26,"is_preprint":false},{"pmid":"32408881","id":"PMC_32408881","title":"Anti-IL-20 antibody improved motor function and reduced glial scar formation after traumatic spinal cord injury in rats.","date":"2020","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32408881","citation_count":25,"is_preprint":false},{"pmid":"21814157","id":"PMC_21814157","title":"IL10 family member genes IL19 and IL20 are associated with recurrent wheeze after respiratory syncytial virus bronchiolitis.","date":"2011","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/21814157","citation_count":24,"is_preprint":false},{"pmid":"28426699","id":"PMC_28426699","title":"Anti-IL-20 monoclonal antibody inhibited inflammation and protected against cartilage destruction in murine models of osteoarthritis.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28426699","citation_count":24,"is_preprint":false},{"pmid":"17069926","id":"PMC_17069926","title":"The murine liver is a potential target organ for IL-19, IL-20 and IL-24: Type I Interferons and LPS regulate the expression of IL-20R2.","date":"2006","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/17069926","citation_count":24,"is_preprint":false},{"pmid":"37884352","id":"PMC_37884352","title":"IL-20 controls resolution of experimental colitis by regulating epithelial IFN/STAT2 signalling.","date":"2024","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/37884352","citation_count":23,"is_preprint":false},{"pmid":"27806114","id":"PMC_27806114","title":"Regulation of IL-20 Expression by Estradiol through KMT2B-Mediated Epigenetic Modification.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27806114","citation_count":22,"is_preprint":false},{"pmid":"27619991","id":"PMC_27619991","title":"A Broad Blockade of Signaling from the IL-20 Family of Cytokines Potently Attenuates Collagen-Induced Arthritis.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27619991","citation_count":22,"is_preprint":false},{"pmid":"30250404","id":"PMC_30250404","title":"The roles of IL-19 and IL-20 in the inflammation of degenerative lumbar spondylolisthesis.","date":"2018","source":"Journal of inflammation (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30250404","citation_count":22,"is_preprint":false},{"pmid":"34403503","id":"PMC_34403503","title":"IL-20 is involved in obesity by modulation of adipogenesis and macrophage dysregulation.","date":"2021","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34403503","citation_count":21,"is_preprint":false},{"pmid":"23006144","id":"PMC_23006144","title":"Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment.","date":"2012","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23006144","citation_count":21,"is_preprint":false},{"pmid":"26297177","id":"PMC_26297177","title":"IL-20 in rheumatoid arthritis.","date":"2015","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/26297177","citation_count":20,"is_preprint":false},{"pmid":"28424238","id":"PMC_28424238","title":"IL-20 Signaling in Activated Human Neutrophils Inhibits Neutrophil Migration and Function.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28424238","citation_count":19,"is_preprint":false},{"pmid":"31947928","id":"PMC_31947928","title":"Effects of IL-1β, IL-20, and BMP-2 on Intervertebral Disc Inflammation under Hypoxia.","date":"2020","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31947928","citation_count":19,"is_preprint":false},{"pmid":"16854693","id":"PMC_16854693","title":"Human fetal membrane expression of IL-19 and IL-20 and its differential effect on inflammatory cytokine production.","date":"2006","source":"The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians","url":"https://pubmed.ncbi.nlm.nih.gov/16854693","citation_count":19,"is_preprint":false},{"pmid":"26440411","id":"PMC_26440411","title":"Anti-IL-20 Monoclonal Antibody Suppresses Prostate Cancer Growth and Bone Osteolysis in Murine Models.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26440411","citation_count":18,"is_preprint":false},{"pmid":"12667095","id":"PMC_12667095","title":"IL-20: a new target for the treatment of inflammatory skin disease.","date":"2003","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/12667095","citation_count":18,"is_preprint":false},{"pmid":"15519673","id":"PMC_15519673","title":"Bacterial endotoxin induces IL-20 expression in the glial cells.","date":"2004","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/15519673","citation_count":17,"is_preprint":false},{"pmid":"26903709","id":"PMC_26903709","title":"The Role of the IL-20 Subfamily in Glaucoma.","date":"2016","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/26903709","citation_count":16,"is_preprint":false},{"pmid":"26176762","id":"PMC_26176762","title":"AMPK/HuR-Driven IL-20 Post-Transcriptional Regulation in Psoriatic Skin.","date":"2015","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/26176762","citation_count":16,"is_preprint":false},{"pmid":"31252033","id":"PMC_31252033","title":"IL-20-Receptor Signaling Delimits IL-17 Production in Psoriatic Inflammation.","date":"2019","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/31252033","citation_count":16,"is_preprint":false},{"pmid":"35486004","id":"PMC_35486004","title":"IL-20 promotes cutaneous inflammation and peripheral itch sensation in atopic dermatitis.","date":"2022","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/35486004","citation_count":15,"is_preprint":false},{"pmid":"34557075","id":"PMC_34557075","title":"Expression of IL-20 Receptor Subunit β Is Linked to EAE Neuropathology and CNS Neuroinflammation.","date":"2021","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34557075","citation_count":15,"is_preprint":false},{"pmid":"31953216","id":"PMC_31953216","title":"IL-20 promotes hypoxia/reoxygenation-induced mitochondrial dysfunction and apoptosis in cardiomyocytes by upregulating oxidative stress by activating the PKC/NADPH oxidase pathway.","date":"2020","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/31953216","citation_count":15,"is_preprint":false},{"pmid":"29998404","id":"PMC_29998404","title":"Cetacea are natural knockouts for IL20.","date":"2018","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/29998404","citation_count":14,"is_preprint":false},{"pmid":"29684756","id":"PMC_29684756","title":"Modulation of Th1/Tc1 and Th17/Tc17 responses in pulmonary tuberculosis by IL-20 subfamily of cytokines.","date":"2018","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/29684756","citation_count":14,"is_preprint":false},{"pmid":"22948742","id":"PMC_22948742","title":"Combination of IL-1 receptor antagonist, IL-20 and CD40 ligand for the prediction of acute cellular renal allograft rejection.","date":"2012","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22948742","citation_count":14,"is_preprint":false},{"pmid":"32622964","id":"PMC_32622964","title":"A single-center observational study on the expression of circulating interleukin-20 levels and predicting outcomes in human chronic heart failure: A 2-year follow-up cohort study: Higher IL-20 levels suggest poorer outcomes in CHF patients.","date":"2020","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32622964","citation_count":13,"is_preprint":false},{"pmid":"23183096","id":"PMC_23183096","title":"Genetic polymorphisms of interleukin 20 (IL-20) in patients with ulcerative colitis.","date":"2012","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/23183096","citation_count":12,"is_preprint":false},{"pmid":"33578994","id":"PMC_33578994","title":"Anti-IL-20 Antibody Protects against Ischemia/Reperfusion-Impaired Myocardial Function through Modulation of Oxidative Injuries, Inflammation and Cardiac Remodeling.","date":"2021","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33578994","citation_count":12,"is_preprint":false},{"pmid":"29242565","id":"PMC_29242565","title":"Anti-IL-20 monoclonal antibody inhibited tumor growth in hepatocellular carcinoma.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29242565","citation_count":11,"is_preprint":false},{"pmid":"29334679","id":"PMC_29334679","title":"The IL20 Genetic Polymorphism Is Associated with Altered Clinical Outcome in Septic Shock.","date":"2018","source":"Journal of innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29334679","citation_count":10,"is_preprint":false},{"pmid":"26162095","id":"PMC_26162095","title":"Neutralizing Anti-IL20 Antibody Treatment Significantly Modulates Low Grade Inflammation without Affecting HbA1c in Type 2 Diabetic db/db Mice.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26162095","citation_count":9,"is_preprint":false},{"pmid":"31238130","id":"PMC_31238130","title":"Murine astrocytes are responsive to the pro-inflammatory effects of IL-20.","date":"2019","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/31238130","citation_count":9,"is_preprint":false},{"pmid":"30333881","id":"PMC_30333881","title":"Anti-IL-20 monoclonal antibody suppresses hepatocellular carcinoma progression.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30333881","citation_count":9,"is_preprint":false},{"pmid":"28514748","id":"PMC_28514748","title":"A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28514748","citation_count":9,"is_preprint":false},{"pmid":"25543042","id":"PMC_25543042","title":"The correlation between IL-20 and the Th2 immune response in human asthma.","date":"2014","source":"Asian Pacific journal of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25543042","citation_count":8,"is_preprint":false},{"pmid":"25071309","id":"PMC_25071309","title":"Reduction of IL-20 Expression in Rheumatoid Arthritis by Linear Polarized Infrared Light Irradiation.","date":"2014","source":"Laser therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25071309","citation_count":8,"is_preprint":false},{"pmid":"34944654","id":"PMC_34944654","title":"IL-20 Cytokines Are Involved in Epithelial Lesions Associated with Virus-Induced COPD Exacerbation in Mice.","date":"2021","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/34944654","citation_count":8,"is_preprint":false},{"pmid":"21109726","id":"PMC_21109726","title":"The association between the IL-20-1723C→G allele on the 1q chromosome and psoriasis triggered or exacerbated by an upper respiratory tract infection in the Chinese Han population.","date":"2010","source":"Dermatology (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/21109726","citation_count":8,"is_preprint":false},{"pmid":"32984900","id":"PMC_32984900","title":"TNFα inhibitors reduce bone loss in rheumatoid arthritis independent of clinical response by reducing osteoclast precursors and IL-20.","date":"2021","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32984900","citation_count":7,"is_preprint":false},{"pmid":"27167908","id":"PMC_27167908","title":"Interleukins (ILs), a fascinating family of cytokines. Part II: ILs from IL-20 to IL-38.","date":"2015","source":"Theoretical biology forum","url":"https://pubmed.ncbi.nlm.nih.gov/27167908","citation_count":6,"is_preprint":false},{"pmid":"37887308","id":"PMC_37887308","title":"IL-20 Cytokines Are Involved in the Repair of Airway Epithelial Barrier: Implication in Exposure to Cigarette Smoke and in COPD Pathology.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37887308","citation_count":6,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50214,"output_tokens":6405,"usd":0.123358},"stage2":{"model":"claude-opus-4-6","input_tokens":10138,"output_tokens":4288,"usd":0.236835},"total_usd":0.360193,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"IL-20 signals through two distinct receptor complexes: a type I complex (IL-20Rα/IL-20Rβ) and a type II complex (IL-22R1/IL-20Rβ); binding of IL-20 to either complex results in STAT3 phosphorylation and activation of STAT-binding promoter elements. IL-19 signals only through type I, while mda-7/IL-24 signals through both.\",\n      \"method\": \"Receptor binding assays, STAT3 phosphorylation assays, STAT-responsive reporter gene assays in cell lines\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct biochemical receptor-ligand binding and signaling assays with multiple cytokines/receptor combinations; foundational paper replicated across the field\",\n      \"pmids\": [\"11564763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"IL-20 induces acanthosis, upregulates S100A7 and keratin 16, and causes persistent nuclear STAT3 activation in reconstituted human epidermis (RHE); it also induces a gene-expression profile consistent with inflammatory responses, wound healing, and altered keratinocyte differentiation.\",\n      \"method\": \"Reconstituted human epidermis (3D skin model) treated with recombinant cytokines; immunostaining for STAT3 nuclear localization; microarray gene expression analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstituted tissue model with multiple orthogonal readouts (histology, immunostaining, transcriptomics); replicated by multiple labs\",\n      \"pmids\": [\"17277128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"IL-20 causes psoriasis-like morphological changes (acanthosis, inhibited keratinocyte terminal differentiation, STAT3 upregulation) in 3D human epidermis models, acting directly on keratinocytes; these effects are distinct from those of IFN-γ and IL-17.\",\n      \"method\": \"3D human epidermis model treated with IL-20 vs. other cytokines; histological analysis; STAT3 assays; differentiation-gene expression\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstituted 3D epidermal model with multiple cytokine comparisons and STAT3-dependence testing; independently corroborates PMID 17277128\",\n      \"pmids\": [\"19330474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"IL-22 induces IL-20 mRNA and protein production in human keratinocytes; IL-17A and TNF-α also induce IL-20 in keratinocytes, and some IL-22 effects on differentiation-regulating genes are partially mediated by endogenously secreted IL-20 (as shown by anti-IL-20 antibody blockade).\",\n      \"method\": \"Keratinocyte cell culture with recombinant cytokines; RT-PCR and ELISA for IL-20; neutralizing anti-IL-20 antibody blockade of IL-22 effects; correlation of IL-20 and IL-22 in patient skin\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ELISA, PCR, antibody neutralization, in vivo mouse model); demonstrates epistatic relationship between IL-22 and IL-20 in keratinocytes\",\n      \"pmids\": [\"19830738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"IL-20 is produced by monocytes (especially myeloid-derived cells) and keratinocytes; IL-20 treatment of keratinocytes upregulates IFN-γ-induced and disease-related genes as determined by microarray; plastic adhesion, β2-integrin activation, and TNF-α stimulate monocyte IL-20 expression.\",\n      \"method\": \"Cell-type–specific IL-20 expression by RT-PCR; in vitro monocyte/keratinocyte stimulation assays; microarray of IL-20-treated keratinocytes; immunohistochemistry with cell-type markers in patient skin\",\n      \"journal\": \"Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — multiple in vitro assays and microarray; single lab, no functional rescue\",\n      \"pmids\": [\"16645593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"IL-20R2 (IL-20Rβ) signaling directly down-regulates antigen-specific CD4+ and CD8+ T cell responses: IL-20R2-knockout mice show elevated IFN-γ and IL-2 from T cells stimulated in vitro and enhanced antigen-specific IFN-γ+ T cell responses in vivo to DNA vaccines.\",\n      \"method\": \"IL-20R2 knockout mice; in vitro T-cell stimulation with Con A or anti-CD3/CD28; DNA vaccine model; contact hypersensitivity model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with defined cellular and in vivo phenotype; multiple functional readouts\",\n      \"pmids\": [\"19124723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"IL-20 activates multiple intracellular signaling pathways in endothelial cells (JAK2/STAT5, ERK1/2, Akt phosphorylation; Rac/Rho GTPase activation; intracellular calcium release) and promotes endothelial tube formation without affecting proliferation or motility; in vivo delivery to ischemic rat hindlimb significantly improves arteriogenesis and blood perfusion.\",\n      \"method\": \"Signaling assays (kinase phosphorylation) in large and microvascular endothelial cells; tube formation assay; rat hindlimb ischemia model with IL-20 delivery\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic in vitro signaling with multiple pathway readouts plus in vivo functional model\",\n      \"pmids\": [\"17878297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IL-20 mediates osteoclastogenesis by up-regulating RANK expression in osteoclast precursor cells and RANKL in osteoblasts; IL-20R1-deficient mice have higher bone mineral density; anti-IL-20 monoclonal antibody completely inhibits osteoclast differentiation induced by M-CSF+RANKL in vitro and protects against ovariectomy-induced bone loss in vivo.\",\n      \"method\": \"In vitro osteoclast differentiation assay with recombinant IL-20 and anti-IL-20 mAb; RT-PCR/Western blot for RANK/RANKL; IL-20R1 knockout mice with DEXA bone density measurement; OVX mouse model\",\n      \"journal\": \"Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro mechanism (RANK/RANKL upregulation) + genetic KO + in vivo pharmacological blockade with multiple readouts\",\n      \"pmids\": [\"21844205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IL-19, IL-20, and IL-24 signaling through type I and type II IL-20 receptors promotes cutaneous S. aureus infection by downregulating IL-1β- and IL-17A-dependent antimicrobial pathways in keratinocytes and skin; antibody blockade of the IL-20 receptor improved infection outcomes in mice.\",\n      \"method\": \"Mouse S. aureus infection model; anti-IL-20R antibody blockade; IL-1β and IL-17A cytokine measurement; human keratinocyte S. aureus exposure assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo infection model with antibody blockade plus human cell data; defines epistatic pathway position of IL-20R signaling upstream of IL-1β/IL-17A\",\n      \"pmids\": [\"23793061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"IL-20 activates lymphatic endothelial cells via PI3K/Akt, ERK1/2, mTOR, and eNOS phosphorylation pathways, induces NO production, causes actin polymerization and tube formation in Matrigel, and drives cell migration at rates comparable to VEGF-C; these effects are PI3K- and mTOR-dependent.\",\n      \"method\": \"Calcium imaging; Akt, ERK1/2, mTOR, eNOS phosphorylation assays; NO production assay; Matrigel tube formation; sprouting/migration assay; pathway inhibitors (wortmannin, rapamycin, PD98059)\",\n      \"journal\": \"Microvascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling readouts with pharmacological inhibitors; single lab\",\n      \"pmids\": [\"19281830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In glioblastoma cells, LPS induces IL-20 expression through a MyD88- and p38 MAP kinase–dependent signaling mechanism (not requiring de novo protein synthesis); dexamethasone inhibits LPS-induced IL-20 expression, indicating glucocorticoid-mediated negative feedback.\",\n      \"method\": \"Primary glial cell and RAW264.7 cultures; LPS stimulation; MyD88-KO mouse-derived glial cells; protein synthesis inhibitor (puromycin/cycloheximide); p38 inhibitor SB203580; RT-PCR\",\n      \"journal\": \"Brain research. Molecular brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO (MyD88) plus pharmacological dissection; single lab\",\n      \"pmids\": [\"15519673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"IL-20 is regulated by hypoxia-inducible factor-1α (HIF-1α): two putative hypoxia response elements in the IL-20 promoter are functional (luciferase reporter assays), CoCl2-induced HIF-1α drives IL-20 expression in multiple cell types, and HIF-1α inhibition suppresses this; in an ischemic stroke rat model, IL-20 is upregulated in peri-infarcted glia-like cells and anti-IL-20 mAb reduces brain infarct size.\",\n      \"method\": \"CoCl2 hypoxia mimicry; HIF-1α inhibition; luciferase promoter activity assays; RT-PCR in multiple cell lines; rat MCAO ischemic stroke model; anti-IL-20 mAb treatment; JAK2/STAT3 and ERK1/2 signaling assays in glioblastoma cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — promoter mutagenesis/reporter + genetic inhibition + in vivo model with functional readout\",\n      \"pmids\": [\"19342680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IL-20 activates quiescent hepatic stellate cells, upregulates TGF-β1 in both hepatocytes and stellate cells, and promotes stellate cell proliferation/migration and collagen I production; in vivo, IL-20R1-deficient mice are protected from CCl4-induced liver fibrosis, and anti-IL-20 antibodies attenuate fibrosis by reducing TGF-β1, TNF-α, and extracellular matrix accumulation.\",\n      \"method\": \"In vitro hepatic stellate cell and hepatocyte stimulation; RT-PCR/ELISA for TGF-β1, collagen; CCl4 mouse liver fibrosis model; IL-20R1 KO mice; anti-IL-20 and anti-IL-20R1 mAb treatment\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + pharmacological blockade + in vitro mechanism; multiple endpoints\",\n      \"pmids\": [\"24763901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IL-20 mRNA is post-transcriptionally regulated in psoriatic keratinocytes by the RNA-binding protein HuR, which relocates to the cytoplasm and stabilizes IL-20 transcripts; AMPK activity is severely impaired in psoriatic epidermis and drives HuR cytoplasmic relocalization; in vivo AMPK inhibition in mouse epidermis reproduces IL-20 overproduction, acanthosis, and hyperkeratosis.\",\n      \"method\": \"RNP-immunoprecipitation with high-throughput sequencing (RIP-Seq) from psoriatic skin; subcellular fractionation and HuR localization; AMPK activity assays; pharmacological AMPK inhibition in mouse epidermis; IL-20 mRNA stability assays\",\n      \"journal\": \"Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — RIP-Seq + in vitro mRNA stability + in vivo AMPK inhibition with defined phenotypic readout\",\n      \"pmids\": [\"26176762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Estrogen (E2) induces IL-20 expression in breast cancer cells through ER-α recruiting the histone methyltransferase KMT2B to the IL-20 promoter, leading to H3K4 methylation; depletion of KMT2B or IL-20 reduces cell proliferation, colony formation, and causes cell cycle arrest.\",\n      \"method\": \"ChIP assay for KMT2B and H3K4 methylation at IL-20 promoter; siRNA knockdown of KMT2B; cell proliferation and colony formation assays; qRT-PCR\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus functional KD; single lab\",\n      \"pmids\": [\"27806114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A transcriptional complex of ERα, GATA3, FOXA1, and ELL3 regulates IL-20 expression in ER+ breast cancer cells; ERα and GATA3 activate IL-20 transcription while FOXA1 represses it; ELL3 associates with ERα to increase its binding affinity to the IL-20 promoter and may prevent FOXA1 binding.\",\n      \"method\": \"ChIP assay; co-immunoprecipitation of the transcriptional complex; siRNA knockdown of individual factors; luciferase reporter assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP + ChIP + reporter assays; single lab\",\n      \"pmids\": [\"28514748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IL-20 receptor signaling (particularly via IL-19) in the imiquimod psoriasis model suppresses dermal CCL2 chemokine production and thereby reduces recruitment of CCL2-driven inflammatory cells including IL-17A-producing γδ T cells, constituting a negative feedback loop since IL-17A induces IL-19 in keratinocytes.\",\n      \"method\": \"Imiquimod-induced psoriasis mouse model; IL-20R knockout/deficient mice; cytokine and chemokine measurements; flow cytometry of infiltrating immune cells\",\n      \"journal\": \"Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with defined cellular mechanism; single lab\",\n      \"pmids\": [\"31252033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IL-20 inhibits key inflammatory functions of activated human neutrophils (phagocytosis, granule exocytosis, migration) by modifying actin polymerization; neutrophils upregulate IL-20R chain expression upon migration and activation under S. aureus infection conditions.\",\n      \"method\": \"Primary human neutrophil isolation; in vitro migration and activation assays; actin polymerization assay; phagocytosis assay; granule exocytosis assay; IL-20R expression by flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional neutrophil assays with mechanistic link to actin; single lab\",\n      \"pmids\": [\"28424238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IL-20 promotes cardiomyocyte apoptosis under hypoxia/reoxygenation by activating the PKC/NADPH oxidase pathway, increasing intracellular Ca2+, elevating oxidative stress, and downregulating AKT; these effects are observed in H9C2 cardiomyoblasts, primary cardiomyocytes, and in rat hearts undergoing I/R injury.\",\n      \"method\": \"H9C2 and primary cardiomyocyte cell culture; hypoxia/reoxygenation model; PKC inhibition; NADPH oxidase activity; Ca2+ imaging; AKT phosphorylation assay; rat I/R model\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissection with inhibitors plus in vivo model; single lab\",\n      \"pmids\": [\"31953216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IL-20 promotes adipocyte differentiation and polarizes bone marrow-derived macrophages toward M1 type; it induces inflammation and macrophage retention in adipose tissue by upregulating TNF-α, MCP-1, netrin 1, and unc5b in macrophages and induces insulin resistance by inhibiting glucose uptake via the SOCS-3 pathway in mature adipocytes.\",\n      \"method\": \"In vitro adipocyte differentiation assay; BMDM polarization assay; ELISA/Western blot for signaling; glucose uptake assay; SOCS-3 pathway analysis; HFD mouse model with anti-IL-20 mAb treatment\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vitro assays with defined pathway (SOCS-3) plus in vivo model; single lab\",\n      \"pmids\": [\"34403503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"IL-20 controls resolution of experimental colitis by signaling in intestinal epithelial cells (IECs) to suppress IFN/STAT2-driven necroptotic cell death; IL-20 activates STAT3 and suppresses IFN-STAT2 signaling in IECs; Il20- and Il20rb-deficient mice are more susceptible to DSS colitis; IL-20 blockade of STAT2 necroptosis in IEC-derived organoids was demonstrated by co-immunoprecipitation and confocal microscopy.\",\n      \"method\": \"Il20 and Il20rb knockout mice; DSS colitis model; IEC-derived 3D organoids; RNA-Seq; co-immunoprecipitation; STAT2 IEC-specific knockout mice; Western blot for STAT3/STAT2; RNAScope\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple genetic KO models + organoids + co-IP + in vivo disease model with mechanistic pathway (STAT2 necroptosis) identified\",\n      \"pmids\": [\"37884352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IL-20 subfamily cytokines (including IL-20) impair the oesophageal epithelial barrier in eosinophilic oesophagitis by downregulating filaggrin and cornified envelope genes via the MAPK/ERK1/2 pathway; Il20R2-deficient mice show preserved filaggrin expression and attenuated EoE; ERK1/2 blockade prevents barrier impairment in patient-derived ALI cultures.\",\n      \"method\": \"Patient-derived oesophageal organoids and ALI cultures; RNA-Seq and mass spectrometry; Il20R2-/- EoE mouse model; ERK1/2 inhibition; immunostaining for filaggrin\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic KO + organoid models + proteomics + pathway inhibition with mechanistic readout\",\n      \"pmids\": [\"35613844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"IL-20 selectively enhances colony formation by CD34+ multipotential hematopoietic progenitors in vitro and in vivo (transgenic overexpression and direct administration in mice), with no effect on erythroid, granulocyte-macrophage, or megakaryocyte progenitors.\",\n      \"method\": \"In vitro colony formation assay of CD34+ progenitors; IL-20 transgenic mice; recombinant IL-20 administration to normal mice; progenitor enumeration and cell-cycle analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro + transgenic + direct in vivo administration; single lab with multiple modalities\",\n      \"pmids\": [\"12855566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IL-20 downregulates COX-2 and PGE2 in human bronchial epithelial and endothelial cells through the IL-22R1/IL-20R2 receptor complex (as determined by flow cytometry of receptor expression and receptor blockade), and inhibits experimental angiogenesis via this COX-2 regulatory pathway.\",\n      \"method\": \"Flow cytometry for receptor expression; COX-2/PGE2 assays with receptor-blocking antibodies; in vitro angiogenesis assay with COX-2 pathway inhibition\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — receptor specificity established by blocking antibody + functional angiogenesis readout; single lab\",\n      \"pmids\": [\"15950941\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IL-20 is a pleiotropic IL-10 family cytokine that signals through two heterodimeric receptor complexes (type I: IL-20Rα/IL-20Rβ; type II: IL-22R1/IL-20Rβ), activating JAK-STAT3 and multiple downstream pathways (ERK1/2, Akt, PKC/NADPH oxidase, MAPK) to regulate keratinocyte proliferation and barrier function, inhibit terminal differentiation via HIF-1α- and HuR/AMPK-controlled expression, promote osteoclastogenesis via RANK/RANKL upregulation, facilitate arteriogenesis and lymphangiogenesis through endothelial tube formation, drive hepatic stellate cell activation and fibrosis via TGF-β1, protect intestinal epithelial cells from IFN/STAT2-driven necroptosis, and modulate T cell and neutrophil responses through IL-20Rβ signaling, while its own transcription is induced downstream of IL-22 and TNF-α in keratinocytes and regulated epigenetically by KMT2B/ERα and post-transcriptionally by AMPK/HuR.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"IL-20 is a pleiotropic IL-10 family cytokine that orchestrates epithelial proliferation, barrier integrity, immune modulation, and tissue remodeling across multiple organ systems. It signals through two heterodimeric receptor complexes—IL-20Rα/IL-20Rβ (type I) and IL-22R1/IL-20Rβ (type II)—to activate STAT3, ERK1/2, PI3K/Akt, and PKC/NADPH oxidase pathways, driving keratinocyte hyperproliferation and inhibition of terminal differentiation (psoriasis-like acanthosis), promoting osteoclastogenesis via RANK/RANKL upregulation, activating hepatic stellate cells through TGF-β1 induction, facilitating arteriogenesis and lymphangiogenesis in endothelial cells, and protecting intestinal epithelial cells from IFN/STAT2-driven necroptosis [PMID:11564763, PMID:17277128, PMID:21844205, PMID:24763901, PMID:17878297, PMID:37884352]. IL-20 also suppresses adaptive and innate immune effector functions, dampening T cell cytokine production and neutrophil phagocytosis/migration, and impairs epithelial barrier function in the esophagus through MAPK/ERK1/2-dependent filaggrin downregulation [PMID:19124723, PMID:28424238, PMID:35613844]. Its own expression is induced downstream of IL-22, TNF-α, and LPS (via MyD88/p38), transcriptionally regulated by HIF-1α and an ERα/KMT2B/GATA3 complex, and post-transcriptionally stabilized by the RNA-binding protein HuR under conditions of impaired AMPK activity [PMID:19830738, PMID:19342680, PMID:26176762, PMID:27806114].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Identifying IL-20's dual receptor usage and primary signaling output resolved how a single cytokine activates STAT3 through two distinct heterodimeric receptor complexes, establishing the signaling framework for all subsequent functional studies.\",\n      \"evidence\": \"Receptor binding assays and STAT3 phosphorylation/reporter assays in transfected cell lines\",\n      \"pmids\": [\"11564763\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of IL-20–receptor complexes not determined\", \"Relative contribution of each receptor complex in different tissues unknown\", \"Downstream transcriptional targets of STAT3 activation not mapped\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrating that IL-20 selectively expands multipotential hematopoietic progenitors revealed an unexpected role beyond epithelial biology, though the receptor complex mediating this effect was not identified.\",\n      \"evidence\": \"Colony formation assays of CD34+ progenitors in vitro; IL-20 transgenic mice and recombinant protein administration in vivo\",\n      \"pmids\": [\"12855566\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor complex responsible on hematopoietic progenitors not determined\", \"Not independently replicated\", \"Physiological significance of progenitor expansion unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Elucidating the transcriptional induction of IL-20 by LPS through MyD88 and p38 MAPK established that IL-20 is a direct innate immune response gene that does not require de novo protein synthesis for its induction.\",\n      \"evidence\": \"LPS stimulation of glial cells from wild-type and MyD88-knockout mice; p38 inhibitor; protein synthesis inhibitors; RT-PCR\",\n      \"pmids\": [\"15519673\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Findings in glioblastoma cells; relevance to myeloid cells not directly shown\", \"Promoter elements mediating LPS response not mapped\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showing that IL-20 suppresses COX-2/PGE2 specifically through the type II receptor (IL-22R1/IL-20Rβ) in bronchial epithelial and endothelial cells provided the first evidence for receptor-complex-specific functional outcomes.\",\n      \"evidence\": \"COX-2/PGE2 assays with receptor-blocking antibodies; angiogenesis assay\",\n      \"pmids\": [\"15950941\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Anti-angiogenic effect via COX-2 contrasts with pro-arteriogenic findings in other endothelial contexts; cell-type specificity unresolved\", \"Single lab finding\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Two independent studies using 3D reconstituted human epidermis and endothelial signaling assays established that IL-20 drives keratinocyte acanthosis with persistent nuclear STAT3 and promotes arteriogenesis via JAK2/STAT5, ERK1/2, and Akt in endothelial cells, revealing tissue-specific pathway utilization.\",\n      \"evidence\": \"3D skin models with immunostaining and microarray; endothelial signaling assays and rat hindlimb ischemia model\",\n      \"pmids\": [\"17277128\", \"17878297\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether arteriogenesis requires STAT3 or alternative STATs not resolved\", \"In vivo confirmation of acanthosis mechanism in human psoriasis lacking\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"A convergence of studies established that IL-20 operates as a downstream effector of IL-22 in keratinocytes, is transcriptionally regulated by HIF-1α under hypoxia, activates lymphangiogenic signaling via PI3K/Akt/mTOR/eNOS, inhibits keratinocyte terminal differentiation, and dampens T cell responses via IL-20Rβ, greatly expanding the cytokine's functional portfolio.\",\n      \"evidence\": \"IL-22 → IL-20 induction in keratinocytes with neutralizing antibody; HIF-1α promoter reporter and rat stroke model; lymphatic endothelial cell signaling assays; 3D epidermis differentiation; IL-20R2 knockout T cell assays and DNA vaccine model\",\n      \"pmids\": [\"19830738\", \"19342680\", \"19281830\", \"19330474\", \"19124723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding of HIF-1α to IL-20 promoter HREs shown by reporter but not ChIP\", \"Whether T cell suppression is mediated by IL-20 vs. other IL-20Rβ ligands not resolved\", \"In vivo lymphangiogenesis not demonstrated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating that IL-20 drives osteoclastogenesis through RANK/RANKL upregulation—with IL-20R1 KO mice showing higher bone density and anti-IL-20 mAb preventing ovariectomy-induced bone loss—established IL-20 as a bone-remodeling cytokine.\",\n      \"evidence\": \"In vitro osteoclast differentiation with anti-IL-20 mAb; IL-20R1 KO mice; ovariectomy model\",\n      \"pmids\": [\"21844205\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of IL-20 vs. IL-19/IL-24 to osteoclastogenesis in vivo not dissected\", \"Signaling pathway downstream of RANK induction not traced\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showing that IL-20 receptor signaling suppresses IL-1β- and IL-17A-dependent antimicrobial pathways during S. aureus skin infection, and that receptor blockade improves outcomes, reframed IL-20 subfamily signaling as a host susceptibility factor exploitable by pathogens.\",\n      \"evidence\": \"Mouse S. aureus skin infection; anti-IL-20R antibody; cytokine/chemokine measurements; keratinocyte assays\",\n      \"pmids\": [\"23793061\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific contribution of IL-20 vs. IL-19/IL-24 in the infection model not separated\", \"Mechanism of antimicrobial gene suppression at the promoter level unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identifying IL-20 as an activator of hepatic stellate cells via TGF-β1 induction, with IL-20R1 KO mice protected from CCl4-induced fibrosis, extended IL-20's pathological roles to liver fibrogenesis.\",\n      \"evidence\": \"In vitro stellate cell/hepatocyte stimulation; CCl4 fibrosis model in IL-20R1 KO mice and with anti-IL-20 mAb\",\n      \"pmids\": [\"24763901\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway from IL-20R to TGF-β1 transcription not delineated\", \"Whether IL-20 acts on cholangiocytes or other hepatic cell types not examined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovering that AMPK impairment in psoriatic epidermis causes cytoplasmic HuR relocalization and IL-20 mRNA stabilization provided a post-transcriptional mechanism for IL-20 overproduction in disease and identified AMPK as an upstream regulator.\",\n      \"evidence\": \"RIP-Seq from psoriatic skin; HuR subcellular fractionation; AMPK activity assays; in vivo AMPK inhibition in mouse epidermis\",\n      \"pmids\": [\"26176762\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific HuR binding site on IL-20 mRNA not mapped\", \"Whether AMPK restoration is sufficient to normalize IL-20 in human psoriasis not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealing that estrogen/ERα recruits KMT2B to the IL-20 promoter for H3K4 methylation-dependent activation in breast cancer cells uncovered an epigenetic regulatory axis linking hormone signaling to IL-20 expression.\",\n      \"evidence\": \"ChIP for KMT2B and H3K4me at IL-20 promoter; siRNA knockdown; proliferation and colony assays in breast cancer cells\",\n      \"pmids\": [\"27806114\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Contribution of IL-20 to breast tumor growth in vivo not tested\", \"Whether KMT2B is required for IL-20 expression in non-cancer contexts unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Parallel studies showed that IL-20 inhibits neutrophil effector functions (phagocytosis, migration) by disrupting actin dynamics and that its receptor-mediated signaling suppresses CCL2-dependent inflammatory cell recruitment in psoriasis, consolidating IL-20 as an immunosuppressive feedback cytokine.\",\n      \"evidence\": \"Primary human neutrophil functional assays with actin polymerization readouts; imiquimod psoriasis model in IL-20R KO mice with flow cytometry\",\n      \"pmids\": [\"28424238\", \"31252033\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular target of IL-20 on actin regulatory machinery not identified\", \"Psoriasis feedback loop data primarily reflect IL-19 rather than IL-20 specifically\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating that IL-20 promotes cardiomyocyte apoptosis via PKC/NADPH oxidase-mediated oxidative stress and Ca²⁺ overload during ischemia-reperfusion extended IL-20's injury-promoting role to the heart.\",\n      \"evidence\": \"Hypoxia/reoxygenation in H9C2 cells and primary cardiomyocytes; PKC inhibition; rat I/R model\",\n      \"pmids\": [\"31953216\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor complex mediating cardiac effects not identified\", \"Single lab; not independently replicated\", \"Whether anti-IL-20 is cardioprotective in clinically relevant models unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing that IL-20 promotes adipogenesis, M1 macrophage polarization, and insulin resistance through SOCS-3-mediated glucose uptake inhibition identified IL-20 as a metabolic inflammation mediator in adipose tissue.\",\n      \"evidence\": \"Adipocyte differentiation and glucose uptake assays; BMDM polarization; anti-IL-20 mAb in HFD mice\",\n      \"pmids\": [\"34403503\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor complex involved in adipocyte signaling not defined\", \"Single lab; independent replication needed\", \"Relative contribution vs. other IL-10 family members in metabolic syndrome unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating that IL-20 subfamily cytokines impair esophageal barrier integrity by downregulating filaggrin via MAPK/ERK1/2, with Il20R2 KO mice protected from eosinophilic esophagitis, extended the barrier-disrupting paradigm beyond skin to mucosal epithelia.\",\n      \"evidence\": \"Patient-derived esophageal organoids and ALI cultures; RNA-Seq; Il20R2 KO EoE mouse model; ERK1/2 inhibition\",\n      \"pmids\": [\"35613844\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual contribution of IL-20 vs. IL-19/IL-24 not dissected\", \"Whether filaggrin downregulation is transcriptional or post-transcriptional not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identifying IL-20 as a protector of intestinal epithelial cells from IFN/STAT2-driven necroptosis during colitis, through STAT3 activation that antagonizes STAT2 signaling, revealed a tissue-repair function and a mechanistic STAT3-vs-STAT2 axis governing epithelial cell fate.\",\n      \"evidence\": \"Il20 and Il20rb KO mice in DSS colitis; IEC-derived organoids; RNA-Seq; STAT2 IEC-specific KO; co-IP for STAT2 necroptotic complex\",\n      \"pmids\": [\"37884352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT3 directly inhibits STAT2 transcription or competes for shared cofactors unknown\", \"Relevance to human IBD not yet confirmed with patient tissue functional studies\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions include the structural basis of IL-20's dual receptor engagement, the determinants of tissue-specific pathway activation (STAT3 vs. ERK vs. PKC), the individual contributions of IL-20 vs. other IL-20Rβ-utilizing cytokines in vivo, and whether IL-20 neutralization has therapeutic efficacy in human disease.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of IL-20 bound to either receptor complex\", \"No systematic comparison of IL-20 vs. IL-19 vs. IL-24 signaling outcomes in identical cell types\", \"Clinical trial data for anti-IL-20 therapy absent from this literature\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 6, 7, 9, 12, 20]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 8, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 3, 4, 7, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 6, 9, 11, 18, 20]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 8, 16, 17]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [1, 2, 3, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"IL20RA\",\n      \"IL20RB\",\n      \"IL22RA1\",\n      \"STAT3\",\n      \"ELAVL1\",\n      \"KMT2B\",\n      \"ESR1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}